110 related articles for article (PubMed ID: 35753289)
1. Tropomyosin receptor kinase protein expression in Thai cholangiocarcinoma: Clinicopathological correlation, expression pattern, and prognosis.
Leepisuth P; Watcharadetwittaya S; Sa-Ngiamwibool P
Ann Diagn Pathol; 2022 Oct; 60():151996. PubMed ID: 35753289
[TBL] [Abstract][Full Text] [Related]
2. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma.
Yang XQ; Xu YF; Guo S; Liu Y; Ning SL; Lu XF; Yang H; Chen YX
World J Gastroenterol; 2014 Apr; 20(14):4076-84. PubMed ID: 24744599
[TBL] [Abstract][Full Text] [Related]
5. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
Jiang YY; Chen H; Xu BL; Wang S
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
[No Abstract] [Full Text] [Related]
7. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma.
Choi S; Park S; Cho YA; Park CK; Ha SY
Pathol Oncol Res; 2020 Oct; 26(4):2587-2595. PubMed ID: 32623639
[TBL] [Abstract][Full Text] [Related]
9. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
10. Pan-TRK Immunohistochemistry and NTRK Gene Fusions in Primary Carcinomas of the Liver.
Zhang D; Liao X
Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):435-440. PubMed ID: 35587529
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
[TBL] [Abstract][Full Text] [Related]
12. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
[TBL] [Abstract][Full Text] [Related]
13. Survival of Patients with Cholangiocarcinoma Receiving Surgical Treatment in an O. viverrini Endemic Area in Thailand: A Retrospective Cohort Study.
Chansitthichok S; Chamnan P; Sarkhampee P; Lertsawatvicha N; Voravisutthikul P; Wattanarath P
Asian Pac J Cancer Prev; 2020 Apr; 21(4):903-909. PubMed ID: 32334449
[TBL] [Abstract][Full Text] [Related]
14. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.
Laohaviroj M; Chamgramol Y; Pairojkul C; Mulvenna J; Sripa B
Asian Pac J Cancer Prev; 2016; 17(1):201-5. PubMed ID: 26838210
[TBL] [Abstract][Full Text] [Related]
16. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
[TBL] [Abstract][Full Text] [Related]
17. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.
Guibourg B; Cloarec E; Conan-Charlet V; Quintin-Roué I; Grippari JL; Le Flahec G; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):719-724. PubMed ID: 32187023
[TBL] [Abstract][Full Text] [Related]
18. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
19. Differential Expression of Sonic Hedgehog Protein in Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Al-Bahrani R; Nagamori S; Leng R; Petryk A; Sergi C
Pathol Oncol Res; 2015 Sep; 21(4):901-8. PubMed ID: 25740074
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW
Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
